# US 2025/0122258 A1 · Compositions and uses of vasoactive intestinal peptide (vip) antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0122258 A1
- Document ID: US20250122258A1
- Status: Published application
- Kind: A1
- Application number: 18/889,859
- Filed: 2024-09-19
- Published: 2025-04-17
- Earliest claimed: 2018-11-15
- Assignees: Emory University
- Applicants: Emory University
- Inventors: Edmund K. Waller; Yiwen Li; Sruthi Ravindranathan; Jian-Ming Li
- Web page: https://patentgrep.com/patent/US20250122258A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 14/57563: {Vasoactive intestinal peptide [VIP]; Related peptides}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C12N 2501/35: Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]
- C12N 2501/515: CD3, T-cell receptor complex
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure relates to VIP antagonist for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

## Claims

### Claim 1

A peptide comprising K P R R P Y X1 X2 N X3 T X4 L R K Q X5 A V X6 K Y X7 N X8 I L N (SEQ ID NO: 11), wherein X1 is A or any amino acid;
X2 is V or any amino acid;
X3 is C or any amino acid;
X4 is S or any amino acid;
X5 is I or any amino acid;
X6 is N or any amino acid;
X7 is M or any amino acid;
X8 is I or any amino acid; and
provided that the peptide is not KPRRPYTDNYTRLRKQMAVKKYLNSILN (SEQ ID NO: 1) or the combination wherein X1 is T, X2 is D, X3 is Y, X4 is R, X5 is M, X6 is K, X7 is L, and X8 is S.

### Claim 2 (depends on 1)

The peptide of claim 1 comprising or consisting of K P R R P Y X1 X2 N X3 T X4 L R K Q X5 A V X6 K Y X7 N X8 I L N (SEQ ID NO: 11),
wherein X1 is A or T, wherein X1 is T only if X2 is V, X3 is C, X4 is S, X5 is I, X6 is N, X7 is M, or X8 is I;
wherein X2 is V or D, wherein X2 is D only if X1 is A, X3 is C, X4 is S, X5 is I, X6 is N, X7 is M, or X8 is I;
wherein X3 is C or Y, wherein X3 is Y only if X1 is A, X2 is V, X4 is S, X5 is I, X6 is N, X7 is M, or X8 is I;
wherein X4 is S or R, wherein X4 is R only if X1 is A, X2 is V, X3 is C, X5 is I, X6 is N, X7 is M, or X8 is I;
wherein X5 is I or M, wherein X5 is M only if X1 is A, X2 is V, X3 is C, X4 is S, X6 is N, X7 is M, or X8 is I;
wherein X6 is N or K, wherein X6 is K only if X1 is A, X2 is V, X3 is C, X4 is S, X5 is I, X7 is M, or X8 is I;
wherein X7 is M or L, wherein X7 is L only if X1 is A, X2 is V, X3 is C, X4 is S, X5 is I, X6 is N, or X8 is I; and
wherein X8 is I or S, wherein X8 is S only if X1 is A, X2 is V, X3 is C, X4 is S, X5 is I, X6 is N, or X7 is M.

### Claim 3 (depends on 1)

The peptide of claim 1 comprising KPRRPYTDNYTRLRKQMAVKKYLNLILN (SEQ ID NO: 10).

### Claim 4 (depends on 1)

The peptide of claim 1, wherein an amino, carboxyl, hydroxyl, or thiol group in the peptide is substituted.

### Claim 5 (depends on 1)

The peptide of claim 1, wherein the peptides is conjugated to a nanoparticle.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising a peptide of claim 1 and pharmaceutically acceptable excipient.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6 in the form of a capsule, tablets, pill, powder, or granule.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6 in the form of a sterilized pH buffered aqueous salt solution.

### Claim 9 (depends on 6)

The pharmaceutical composition of claim 6 in the form of a container configured to spray a liquid or sealed container with a propellant.

### Claim 10 (depends on 1, 2, 3, 4)

A nucleic acid encoding a peptide as in any of claims 1-4 in operable combination with a promoter.

### Claim 11 (depends on 1)

A recombinant vector comprising the nucleic acid of claim 1.

### Claim 12 (depends on 7)

A cell comprising a recombinant vector of claim 7.

### Claim 13 (depends on 1, 2, 3, 4)

A method of augmenting T-cell activation and ex vivo expansion comprising mixing T cells with a peptide as in any of claims 1-4.

### Claim 14 (depends on 13)

The method of claim 13 wherein mixing T cells is in combination with an anti-CD3 antibody and/or anti-CD28 antibody.

### Claim 15 (depends on 13)

The method of claim 13, wherein mixing T cells is in combination with phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor.
